TY - JOUR
T1 - Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder
AU - Fontenelle, Leonardo F.
AU - Mendlowicz, Mauro V.
AU - Miguel, Euripedes C.
AU - Versiani, Marcio
PY - 2005/6/7
Y1 - 2005/6/7
N2 - While serotonin reuptake inhibitors (SRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), as many as 40-60% of patients fail to respond to adequate trials with these drugs. In this study, we describe the case of a patient with an SRI-resistant OCD who was successfully treated with a combination of citalopram (a selective SRI) and reboxetine (a selective noradrenaline reuptake inhibitor (SNRI)). This report suggests that future studies accessing the efficacy of the SRI-SNRI combination in treatment resistant OCD are needed.
AB - While serotonin reuptake inhibitors (SRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), as many as 40-60% of patients fail to respond to adequate trials with these drugs. In this study, we describe the case of a patient with an SRI-resistant OCD who was successfully treated with a combination of citalopram (a selective SRI) and reboxetine (a selective noradrenaline reuptake inhibitor (SNRI)). This report suggests that future studies accessing the efficacy of the SRI-SNRI combination in treatment resistant OCD are needed.
KW - Citalopram
KW - Obsessive-compulsive disorder
KW - Reboxetine
UR - https://www.scopus.com/pages/publications/19444382365
U2 - 10.1080/15622970510029740
DO - 10.1080/15622970510029740
M3 - Article
C2 - 16097406
AN - SCOPUS:19444382365
SN - 1562-2975
VL - 6
SP - 57
EP - 59
JO - The World Journal of Biological Psychiatry
JF - The World Journal of Biological Psychiatry
IS - 1
ER -
